泮托拉唑钠水合物
泮托拉唑钠水合物 性质
| 储存条件 | 4°C, protect from light |
|---|---|
| 溶解度 | 易溶于水和乙醇（96%），几乎不溶于己烷。 |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| 主要应用 | pharmaceutical (small molecule) |
| InChI | 1S/C16H16F2N3O4S.Na.H2O/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;;/h3-7,15-16,21H,8H2,1-2H3;;1H2/q-1;+1; |
| InChIKey | QHNXIKDJFYGZTL-UHFFFAOYSA-N |
| SMILES | [Na+].FC(F)Oc1cc2c(cc1)[N-]C(N2)[S](=O)Cc3nccc(c3OC)OC.O |
泮托拉唑钠水合物 用途与合成方法
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells.
Pantoprazole sodium hydrate can block exosome release. Pantoprazole sodium hydrate inhibits the activity of V-H
+
-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin.
Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats.
| Animal Model: | Mice bearing MCF-7 or A431 xenografts |
| Dosage: | 200 mg/kg |
| Administration: | IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.) |
| Result: |
Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
Significantly increased tumor growth delay with a single dose with Doxorubicin. There is no effect on growth delay alone. |
泮托拉唑钠水合物 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-05 | HY-17507BR | 泮托拉唑钠水合物 | 164579-32-2 | 50 mg | 333 |
| 2026-06-05 | HY-17507BR | 泮托拉唑钠水合物 | 164579-32-2 | 100 mg | 500 |
